Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Daré Bioscience, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
DARE
Nasdaq
2834
darebioscience.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Daré Bioscience, Inc.
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?
- Oct 30th, 2024 1:40 pm
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
- Oct 23rd, 2024 4:30 pm
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
- Oct 21st, 2024 12:05 pm
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
- Aug 26th, 2024 12:00 pm
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
- Aug 13th, 2024 12:00 pm
Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates
- Aug 12th, 2024 9:15 pm
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
- Aug 12th, 2024 8:01 pm
Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024
- Aug 5th, 2024 12:00 pm
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
- Jul 19th, 2024 12:00 pm
Daré Bioscience Announces Reverse Stock Split
- Jun 27th, 2024 12:00 pm
Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder
- Jun 24th, 2024 12:00 pm
Q1 2024 Dare Bioscience Inc Earnings Call
- May 15th, 2024 4:27 pm
Dare Bioscience Inc (DARE) (Q1 2024) Earnings Call Transcript Highlights: Strategic Moves Amid ...
- May 15th, 2024 7:13 am
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
- May 14th, 2024 12:00 pm
Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
- May 7th, 2024 12:00 pm
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
- May 2nd, 2024 12:00 pm
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
- Apr 30th, 2024 11:30 am
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
- Apr 23rd, 2024 12:00 pm
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
- Apr 11th, 2024 12:00 pm
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 8:05 pm
Scroll